Clinical Trial Update: Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a combination including Ch14.18, sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in high risk neurobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Ch14.18 (dacetuzumab? (Note: Ch14.18 is dinutuximab beta or similar; please verify exact derivative))
• ISOTRETINOIN (Isotretinoin)
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: High Risk Neuroblastoma | Phase 3 | Status: COMPLETED | Results posted: 2015-02-19